Fig. 1From: MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine designFlow chart of clonal mutation analysis and HLA-binding neo-antigen prediction for lung adenocarcinoma patientsBack to article page